Novartis/Nestle May See Cycle Of Negotiations Over Alcon Option Rights In 4Q 2009

Tuesday, February 10, 2009

Comments

Financial Times

Negotiations between Novartis (NYSE:NVS) and Nestle (VTX:NESN) over their option rights – allowing Novartis to acquire the remaining stake Nestle owns in Alcon (NYSE:ACL) – may see another cycle of negotiations in the fourth quarter, two industry attorneys speculated.

Full Story

A 40 y.o. female pictured below comes to the office with swelling of both upper lids, mild shortness of breath and symptoms of dry eyes. One would expect to see as part of her work up:
1. A monocytic B cell infiltrate of her lacrimal glands
2. Pain on palpation of her lacrimal glands.
3. An elevated ACE.
4. A history of breast cancer.
Check The Answer

VISUPLAN 500 Non-Contact Tonometer
The measurement of intraocular pressure ... view product
Selecta Trio™ YAG Laser, SLT and Photocoagulation
The Lumenis Selecta® Trio™ ... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us

AdGlare Leaderboard

Novartis/Nestle May See Cycle Of Negotiations Over Alcon Option Rights In 4Q 2009

Comments

Related Categories

Refractive Products and Equipment »

Corneal and Refractive Diagnostics »

Cataract Products and Equipment »

Quick Quiz

A 40 y.o. female pictured below comes to the office with swelling of both upper lids, mild shortness of breath and symptoms of dry eyes. One would expect to see as part of her work up:

AdGlare RMR Ad

Cataract Featured Products

VISUPLAN 500 Non-Contact Tonometer

Selecta Trio™ YAG Laser, SLT and Photocoagulation

Follow OphthalmologyWeb

AdGlare RMR2

Write for Us